The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 01, 2020
Filed:
Apr. 04, 2018
Applicant:
Engmab Sarl, Boudry, CH;
Inventors:
Minh Diem Vu, Wollerau, CH;
Klaus Strein, Weinheim, DE;
Ekkehard Moessner, Kreuzlingen, CH;
Ralf Hosse, Cham, CH;
Oliver Ast, Bassersdorf, CH;
Anne Freimoser-Grundschober, Zurich, CH;
Marina Bacac, Zurich, CH;
Tanja Fauti, Zurich, CH;
Christian Klein, Bonstetten, CH;
Pablo Umana, Wollerau, CH;
Samuel Moser, Rotkreuz, CH;
Assignee:
ENGMAB SARL, Boudry, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01); G01N 33/68 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C12N 5/07 (2010.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); C07K 16/3061 (2013.01); G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/66 (2013.01); C07K 2317/71 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 5/06 (2013.01); C12N 15/63 (2013.01); G01N 2333/7151 (2013.01); G01N 2500/04 (2013.01);
Abstract
An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent.